BioPharmSignal logoBioPharmSignal

Biotech News

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

CRISPR Therapeutics (CRSP)CRISPR Therapeutics2026-06-25 13:46 ESTFinancing

ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons

Open original release

Related news

CRSPCRISPR Therapeutics2026-06-25 13:46 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-06-25 13:46 EST

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

CRSPCRISPR Therapeutics2026-06-25 13:46 EST

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

CRSPCRISPR Therapeutics2026-06-25 13:46 EST

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

CRSPCRISPR Therapeutics2026-06-25 13:46 EST

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

CRSPCRISPR Therapeutics2026-06-25 13:46 EST

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

CRSPCRISPR Therapeutics2026-06-25 13:46 EST

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

CRSPCRISPR Therapeutics2026-06-25 13:46 EST

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

CRSPCRISPR Therapeutics2026-06-25 13:46 EST

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

CRSPCRISPR Therapeutics2026-06-25 13:46 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

View all latest news

CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company with exposure to cell therapy and genetic medicine. Investors watch the company for how its editing platform broadens beyond the first commercial and clinical milestones.

Recent company news

CRSPCRISPR Therapeutics2026-06-26 08:45 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-06-26 08:45 EST

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

CRSPCRISPR Therapeutics2026-06-26 08:45 EST

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

CRSPCRISPR Therapeutics2026-06-26 08:45 EST

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

CRSPCRISPR Therapeutics2026-06-26 08:45 EST

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States